Novel Approaches to Treating Neonatal Epilepsy
Researchers at Northwestern Medicine have identified a potential new path for treating neonatal-onset epilepsy caused by mutations in the KCNQ2 gene. This genetic disorder typically triggers seizures within the first few days of life, causing severe complications in brain development. Affected infants often experience profound developmental delays, struggle to acquire language, and face significant motor impairment. Medical teams currently lack disease-modifying therapies for this condition, leaving a critical gap in pediatric neurology. The findings from this investigation were published in the Proceedings of the National Academy of Sciences.
Alfred L. George, Jr., MD, who chairs the Department of Pharmacology at the Feinberg School of Medicine, served as the senior author on this project. His team centered their work on the KCNQ2 gene. Under normal conditions, this gene codes for a potassium channel that functions as a neural brake. It prevents brain cells from firing too frequently or becoming hyperactive. When a patient has a pathogenic KCNQ2 variant, this braking mechanism fails. The result is excessive neuronal activity, which manifests as seizures and disrupts the normal course of early neurodevelopment.
Unlocking the Potential of Protein Synthesis Regulation
The study explored how the body regulates KCNQ2 protein synthesis to determine if researchers could force the production of more functional channels. Investigators analyzed brain RNA datasets from both humans and mice to map the regulatory environment surrounding the gene. They discovered the presence of an upstream open reading frame, or uORF, which acts as a secondary start site for protein synthesis. Ribosomes are the cell's internal factories for producing proteins, but they often stall at these uORF sites. This stalling reduces the efficiency with which the cell produces the main KCNQ2 protein.
By identifying this bottleneck, the researchers developed a strategy to bypass it. The team used DNA base editing to effectively delete or inactivate the uORF in cultured cell samples. The results were clear: the cells responded by increasing the synthesis of the KCNQ2 protein. George noted that the team didn't just see a rise in protein levels, they confirmed that the newly synthesized channels were functional. This distinction is critical for potential clinical applications, as the goal is to replace the lost braking power of the potassium channels with working, healthy versions.
Implications for Future Gene Therapy
The success of the laboratory trials suggests a path toward a permanent solution for KCNQ2-related epilepsy. If researchers can prove that inactivating the uORF works consistently in animal models, it could establish a proof-of-concept for human gene therapies. The team is now expanding their testing into mouse models to observe how the intervention affects seizure frequency and long-term neurological development in vivo. This approach may also offer benefits beyond the KCNQ2 gene, as other forms of epilepsy might be subject to similar regulatory control mechanisms.
Dalton Huey, a student in the Driskill Graduate Program in Life Sciences, led the study. He worked alongside a group of researchers including Eduardo Guadarrama, Christine Simmons, and Qianru Li. Their work received support from the National Institutes of Health and the American Heart Association. The project highlights a growing shift in neurology toward addressing the underlying genetic mechanics of disease rather than merely managing symptoms. While clinical implementation remains a future goal, the discovery of this regulatory element provides a specific, actionable target for drug developers and gene therapists alike. Doctors and families will watch for further results in upcoming murine studies as the team advances this work.